Moore Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Moore Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-200,000	Closed	-$8.56M	–	158
2019 Q4	$8.56M	Sell	200,000 -41,653	-17%	-$1.81M	0.28%	96
2019 Q3	$8.7M	Sell	241,653 -21,673	-8%	-$657K	0.35%	89
2019 Q2	$7.04M	Sell	263,326 -44,124	-14%	-$1.13M	0.17%	125
2019 Q1	$8.26M	Buy	+307,450	New	+$7.18M	0.25%	107
2016 Q1	–	Sell	-100,000	Closed	-$3.56M	–	234
2015 Q4	$3.56M	Buy	+100,000	New	+$3.52M	0.11%	159
2015 Q2	–	Sell	-80,000	Closed	-$2.61M	–	407
2015 Q1	$2.61M	Buy	+80,000	New	+$2.75M	0.06%	242

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Moore Capital Management's ACAD Position: Q1 2020 in Review

Moore Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 200,000 shares — an estimated $8.56M sold.

Moore Capital Management first reported a position in ACAD in Q1 2015 and held it in 6 quarters. The position peaked at $8.7M in Q3 2019. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

Moore Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Moore Capital Management sold 200,000 Acadia Pharmaceuticals shares in Q1 2020, an estimated $8.56M.
Moore Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Moore Capital Management's Acadia Pharmaceuticals position peaked at $8.7M in Q3 2019.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Moore Capital Management's 13F filing for Q1 2020, filed 15 May 2020.